Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. Dezember 2019 16:30 ET | Quelle: BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference

PALO ALTO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday,...
18. Dezember 2019 07:30 ET | Quelle: BridgeBio Pharma, Inc.; Medison Pharma Ltd.

BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A

BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences, a company focused on developing and commercializing a treatment for Molybdenum Cofactor...
16. Dezember 2019 07:30 ET | Quelle: BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member

PALO ALTO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced it has appointed Jennifer Cook to its Board of Directors and will leverage her considerable...
09. Dezember 2019 07:30 ET | Quelle: BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs

PALO ALTO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Eli...
05. Dezember 2019 19:35 ET | Quelle: BridgeBio Pharma, Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November...
03. Dezember 2019 07:30 ET | Quelle: BridgeBio Pharma, Inc.

BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A

BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United...
27. November 2019 16:30 ET | Quelle: BridgeBio Pharma, Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of...
07. November 2019 16:13 ET | Quelle: BridgeBio Pharma, Inc.

BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress

Multiple clinical and pre-clinical milestones achieved across the BridgeBio portfolioDelivered pipeline growth with the addition of BBP-418 for limb-girdle muscular dystrophy type 2iEnded quarter with...
24. September 2019 07:00 ET | Quelle: BridgeBio Pharma, Inc.

Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

PHOENIX, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio...
05. September 2019 16:00 ET | Quelle: BridgeBio Pharma, LLC.

BridgeBio Pharma’s Origin Biosciences Presents New Data on the Natural History of Molybdenum Cofactor Deficiency (MoCD) Type A at the Society of the Study of Inborn Errors of Metabolism (SSIEM) Conference

This landmark study is a comprehensive global survey of the natural history of MoCD Type AResults continue to suggest urgent need for new therapies in MoCD Type A, with median survival of <4 years...

Vorherige Seite

Nächste Seite